Decoglurant

Decoglurant

Systematic (IUPAC) name
5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine
Legal status
Legal status	Development terminated
Identifiers
CAS Number	911115-16-7
ATC code	none
PubChem	CID 71533696
ChemSpider	32695160
Chemical data
Formula	C21H11F6N5
Molar mass	447.336 g/mol
SMILES C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F
InChI InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29) Key:DMJHZVARRXJSEG-UHFFFAOYSA-N

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu₂ and mGlu₃ receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.^[1][2] Decoglurant progressed as far as phase II clinical trials^[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.^[3][4]

See also

• Basimglurant
• RO4491533

References

1. "Roche - Pipeline". 2014. Retrieved 2014-08-01.
2. "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01.
3. "Roche - Pipeline" (PDF). 2015. Retrieved 2015-05-14.
4. Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal.

External links

• Decoglurant - AdisInsight - Springer